Log In
BCIQ
Print this Print this
 

IkT-001Pro

  Manage Alerts
Collapse Summary General Information
Company Inhibikase Therapeutics Inc.
DescriptionBCR-ABL tyrosine kinase inhibitor
Molecular Target BCR-ABL tyrosine kinase (BCR-ABL)
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPreclinical
Standard Indication Infectious (unspecified)
Indication DetailsTreat progressive multifocal leukoencephalopathy (PML)
Regulatory Designation U.S. - Orphan Drug (Treat progressive multifocal leukoencephalopathy (PML))
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today